What is the half-life of Retatrutide?

Retatrutide has a half-life of ~6 days, which is why it's typically administered Once weekly for optimal therapeutic effect.

How do I reconstitute Retatrutide?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Growth Hormone

Phase 3

Retatrutide

Also known as: LY3437943, Triple G, GGG Agonist

Overview

Key Facts

Primary Goal: A novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

A novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, retatrutide has produced the highest weight loss ever recorded in an obesity clinical trial, representing a potential paradigm shift in pharmacological weight management. Half-Life ~6 days Typical Dose 1–12 mg Frequency Once weekly Cycle Length Ongoing / indefinite under medical supervision

Dosing Information

Half-Life

~6 days

Typical Dose

1–12 mg

Frequency

Once weekly

Cycle Length

Ongoing / indefinite under medical supervision

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 3

Phase 2 results published in NEJM showed retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks, with 26% of participants losing over 30% of body weight — the highest ever reported in a clinical trial. A sub-study demonstrated 86% relative reduction in liver fat. Multiple Phase 3 trials (TRIUMPH program) are underway across obesity, type 2 diabetes, and MASH indications. Eli Lilly anticipates potential FDA submission by 2026.